We are live on ! Find out more

NIKI

Niki BioSolutions

NIKI

Market cap $1.44M

1.77 USD

-0.19

9.69%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

1.70

-0.07

3.95%

1 day

-9.69%

5 days

-11.5%

1 month

-63.88%

3 months

-82.6%

6 months

-79.95%

Year to date

-79.95%

1 year

-79.95%

5 years

-79.95%

10 years

-79.95%

About: Niki BioSolutions Inc is a clinical-stage life sciences company focused on unmet medical needs and providing genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations. Its activities include the development and application of proprietary technologies to support precision medicine across therapeutic areas including brain health and oncology. The company also collaborates with academic centers, disease foundations, and biopharmaceutical companies.

Employees: 2

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine

NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use

Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine

Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research

Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer's clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs through advanced genomic and biomarker testing, today announced that DiamiR Biosciences, its wholly owned subsidiary, has signed an agreement to perform apolipoprotein E (APOE) genotyping for Charter Research, a multi-site clinical research organization that conducts trials in Alzheimer's disease, Parkinson's disease, metabolic liver disease, psychiatric conditions, and weight management. The APOE gene is among the most studied genetic risk factors in neurodegeneration, and APOE status is increasingly used to inform eligibility, safety monitoring, and risk stratification in Alzheimer's disease trials.

Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research

Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series

Company's blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome

Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series

Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002

Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer's biomarker cohort PRINCETON, N.J., and NEW HAVEN, Conn.

Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomarker testing solutions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

NEW HAVEN, CT and PRINCETON, NJ, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomarker testing solutions, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City.

Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

See News Rankings

Price charts implemented using Lightweight Charts™